thalidomide has been researched along with Melena in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Melena: The black, tarry, foul-smelling FECES that contain degraded blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 5.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 1.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Heo, Y | 1 |
| Park, HS | 1 |
| Shin, CS | 1 |
| Yoo, KC | 1 |
| Kim, D | 1 |
| Lee, T | 1 |
| Santos, S | 1 |
| Bernardes, C | 1 |
| Borges, V | 1 |
| Ramos, G | 1 |
| Abrantes, J | 1 |
| Fernandes, C | 1 |
| Vieira, CL | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Izquierdo Navarro, Mdel C | 1 |
| Hernando Verdugo, M | 1 |
| Cardaba Garcia, E | 1 |
| Sanchez Sanchez, MT | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
1 review available for thalidomide and Melena
| Article | Year |
|---|---|
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
5 other studies available for thalidomide and Melena
| Article | Year |
|---|---|
Successful Treatment of Life-Threatening Small Bowel Bleeding With Thalidomide After Living Donor Kidney Transplantation: A Case Report.
Topics: Aged; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Kidney | 2019 |
Gastric antral vascular ectasia (GAVE) and hereditary hemorrhagic telangiectasia (HHT): two different conditions, one treatment.
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Bevacizumab; Combined Modality Therapy; Erythrocy | 2020 |
Pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasia.
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Arteriovenous Malformations; Bevacizumab; Endosco | 2019 |
Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias.
Topics: Aged; Anemia; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Male; M | 2016 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |